in European Journal of Endocrinology
View More View Less
Full access

Ethylestrenol (Δ4-17α-ethyl-17-hydroxyestrene) has recently been made available by Organon (Oss) for clinical trials as an oral anabolizer. In the pharmacological studies performed by Overbeek et al. (1961) at Organon it has been demonstrated that ethylestrenol has in animal tests a more favourable anabolic/androgenic ratio than such currently employed substances as methyltestosterone (20 times more favourable), ethylnortestosterone (6 times more favourable) and Δ1-methyltestosterone.

In clinical trials so far performed,2 ethylestrenol was shown to have a marked N-retaining effect; according to recent studies a significant decrease of the total urinary 17-KS-excretion is not produced in male persons treated with ethylestrenol in therapeutic doses; the minimal progestative dose of ethylestrenol was shown to be 1 mg daily (glycogen deposition test of Ferin).

Bodyweight, appetite and psychic tonus were reported to be favourably influenced by the treatment with ethylestrenol.

Organon, Oss, kindly supplied us with this new oral anabolizer for clinical trials. The


     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 73 73 4
Full Text Views 0 0 0
PDF Downloads 0 0 0